Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 456906 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs BI 456906 (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 27 Jul 2017 Status changed from not yet recruiting to recruiting.
- 27 Jun 2017 Planned End Date changed from 17 Apr 2018 to 5 Jun 2018.
- 27 Jun 2017 Planned primary completion date changed from 17 Apr 2018 to 5 Jun 2018.